Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Disrupting Androgen Receptor Transactivation Domains to Identify Lead Compounds with Potential to be Optimized and Developed into Prostate Cancer Therapeutics

Fancher, Ashley/ T (2019) Disrupting Androgen Receptor Transactivation Domains to Identify Lead Compounds with Potential to be Optimized and Developed into Prostate Cancer Therapeutics. Doctoral Dissertation, University of Pittsburgh. (Unpublished)

Download (4MB) | Preview


Prostate cancer (PCa) is the leading cause of cancer in men in the USA, with more than 160,000 new cases each year. PCa patients receiving standard of care androgen deprivation therapy (ADT) eventually acquire what’s known as castration resistant prostate cancer (CRPC), and 20% of all PCa cases progress to this metastatic and incurable form of the disease. PCa is the second leading cause of cancer-related death in American men. Current FDA approved drugs for CRPC only provide a 2-5-month survival benefit due to the emergence of resistance to these therapies. Resistance involves continued androgen receptor (AR) signaling despite castrate serum levels of androgens. CRPC cells express elevated levels of both full-length AR (AR-FL), and constitutively active AR splice variants which lack the ligand binding domain (LBD) and display altered AR coactivator interactions, both of which contribute to persistent AR signaling. Overexpression of steroid-receptor coactivators are implicated in the progression of CRPC and amplify AR-mediated transcription by binding to either the activation function 2 (AF-2) surface formed by the AR-LBD, or the activation function 1 (AF-1) surface located in the amino-terminal domain of the receptor. Coactivator binding interactions enhance the recruitment of the basal transcriptional machinery and activate the transcription of AR target genes. Our lab has designed a screening paradigm to identify compounds with novel mechanisms of action to prevent or delay resistance. The screening paradigm uses a primary high content screening assay (HCS) designed to identify compounds that inhibit or disrupt protein-protein interactions (PPI’s) between AR and one of its coactivators, transcriptional intermediary factor 2 (TIF2), together with panels of counter screens and characterization assays to prioritize hit compounds that inhibit or disrupt AF-2 and/or AF-1 transactivation. The ideal hit compound would prevent the transcription of both AR-FL and AR-V7 thereby providing a dual approach to preventing CRPC progression.


Social Networking:
Share |


Item Type: University of Pittsburgh ETD
Status: Unpublished
CreatorsEmailPitt UsernameORCID
Fancher, Ashley/ Tashley.fancher3@gmail.comasf420000-0003-3823-2766
ETD Committee:
TitleMemberEmail AddressPitt UsernameORCID
Thesis AdvisorJohnston, Paul/
Committee MemberGold, Barry/
Committee MemberXie,
Committee MemberWang,
Date: 27 June 2019
Date Type: Publication
Defense Date: 25 April 2019
Approval Date: 27 June 2019
Submission Date: 3 June 2019
Access Restriction: No restriction; Release the ETD for access worldwide immediately.
Number of Pages: 224
Institution: University of Pittsburgh
Schools and Programs: School of Pharmacy > Pharmaceutical Sciences
Degree: PhD - Doctor of Philosophy
Thesis Type: Doctoral Dissertation
Refereed: Yes
Uncontrolled Keywords: Assay Development, Castration Resistance, Drug Discovery, High Content Screening, Prostate Cancer
Date Deposited: 27 Jun 2019 16:34
Last Modified: 27 Jun 2019 16:34


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item